Briffault, ErikReyes, RicardoGarcía García, PatriciaRouco Taboada, HelenaDíaz Gómez, LuisArnau, María RosaÉvora, CarmenDíaz Rodríguez, PatriciaDelgado, Araceli2025-11-112025-11-112024-11-20Briffault E, Reyes R, Garcia-Garcia P, Rouco H, Diaz-Gomez L, Arnau MR, Evora C, Diaz-Rodriguez P, Delgado A. SFRP1-Silencing GapmeR-Loaded Lipid-Polymer Hybrid Nanoparticles for Bone Regeneration in Osteoporosis: Effect of Dosing and Targeting Strategy. Int J Nanomedicine. 2024;19:12171-12188 https://doi.org/10.2147/IJN.S476546https://hdl.handle.net/10347/43674Osteoporosis is a metabolic disorder characterized by the loss of bone mass and density. Nucleic acid-based therapies are among the most innovative approaches for osteoporosis management, although their effective delivery to bone tissue remains a challenge. In this work, SFRP1-silencing GampeR loaded-nanoparticles were prepared and functionalized with specific moieties to improve bone targeting and, consequently, therapeutic efficacy. SFRP1-silencing would promote osteoblastic differentiation by enhancing the WNT/β-catenin pathway and thus diminishing the progression of osteoporosis.engAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/OsteoporosisBone targetingNanoparticle dose-effectGene therapyAptamerAlendronateMicro-CT3209 Farmacologíajournal article10.2147/IJN.S4765461178-2013open access